Company intelligence / Profile preview

LongeVC

Ownership: Private
Development stage: Other

Overview

LongeVC does not conduct its own clinical trials. Its portfolio includes early-stage to phase I programs through investments in biotech startups such as Rubedo Life Sciences (RLS‑1496 for atopic dermatitis/psoriasis entering phase I), AOA Dx (liquid biopsy for ovarian cancer), PreComb Therapeutics (“tumor twins” for personalized oncology), Turn Biotechnologies (“cell rejuvenation” therapies), among others. These programs are at various stages from preclinical validation to early human trials.

Therapeutic areas: OncologyImmunologyOtherPsychiatryDermatologyOphthalmologyInfectious Diseases
Industry: Investors

Partnerships

JKR Investment GroupLongevity Science FoundationLongevity Biotech Association

Beyond the preview

Go deeper on LongeVC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LongeVC.

Explore the full profile